[The effect of salmeterol on the number of hypodense eosinophils, eosinophilic cationic protein levels ECP in serum, bronchial hyperresponsiveness and lung function test in patients with bronchial asthma].
The aim of the study was to compare the influence of salmeterol xinofoate on blood hypodense eosinophil numbers ECP level in serum and sputum, and on lung function tests (VC, FEV1), bronchial hyperresponsiveness (PC20) Lung function tests (FEV1, VC), bronchial histamine challenge (PC20) and measurements of hypodense eosinophils number and ECP level in sputum and serum were done before two and six weeks after treatment with 50 micrograms salmeterol twice daily. Hypodense eosinophils were measured by Kuo et all, ECP by radioimmunosorbent assay using ECP RIA kit Pharmacia. Normal range of ECP is 2.3-15 micrograms/L Hyperreactivity by standard bronchial provocation techniques. The lung function tests (VC, FEV1, FEV1%VC) were measured with Pneumoscreen.


RESULTS
Eosinophil number decrease after treatment: 42.7 +/- 18.3 before vs 23.4 +/- 8.7 after. ECP level had decreased in serum 53 +/- 24 micrograms/L before and 32 +/- 12 micrograms/L after 2 weeks and 36 +/- 13 micrograms/L after 6 weeks: in sputum 2345 +/- 489 micrograms/g before and 1342 +/- 894 micrograms/g after 2 weeks 1741 micrograms/g after 6 weeks. Lung function tests had improved during the observation and hyperresponsiveness had decreased (0.08 +/- 0.1 microgram/ml before 0.24 +/- 0.2 microgram/ml after 2 week sand 0.4 +/- 0.16 after 6 weeks.


CONCLUSIONS
ECP in serum and sputum in asthmatic patients is higher then in normal patients. Salmeterol improved lung function tests, decreased bronchial responsiveness, decreased hypodense eosinophils number and ECP concentration in serum and sputum.


CONCLUSIONS
This date suggested that salmeterol modified bronchial responsiveness and protected the bronchial inflammation.
Chazan
R
R
Katedry i Kliniki Chorób Wewnetrznych i Pneumonologii Akademii Medycznej.
Grubek-Jaworska
H
H
Hermanowicz-Salomon
J
J
Droszcz
W
W
D000328:Adult; D000420:Albuterol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology*; D001798:Blood Proteins / Q000032:analysis / Q000187:drug effects*; D001980:Bronchi / Q000187:drug effects*; D001985:Bronchial Provocation Tests; D001993:Bronchodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000187:drug effects*; D006801:Humans; D018655:Lymphocyte Count / Q000187:drug effects*; D008875:Middle Aged; D012129:Respiratory Function Tests; D012260:Ribonucleases; D000068299:Salmeterol Xinafoate; D013183:Sputum / Q000737:chemistry
D001798:Blood Proteins; D001993:Bronchodilator Agents; D047091:Eosinophil Granule Proteins; D000068299:Salmeterol Xinafoate; D012260:Ribonucleases; D000420:Albuterol
Wpływ salmeterolu na liczbe granulocytów kwasochłonnych hipodensyjnych, stezenie eozynofilowego białka kationowego ECP w surowicy, badania czynnościowe układu oddechowego i nadreaktywność oskrzelowa u chorych na astme oskrzelowa.